December 17, 2018
Chimeric antigen receptor T-cell therapy has improved health outcomes at a more cost-effective rate than other cancer treatments, according to a study presented at ASH Annual Meeting and Exposition. Data suggest that price increases of pharmaceutical oncology treatments have outpaced survival improvements. However, these study findings reveal that chimeric antigen receptor (CAR) T-cell therapy represents...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand